论文部分内容阅读
目的:探讨丹参注射液联合口服胰激肽原酶肠溶片用于糖尿病微血管病变的临床治疗效果。方法:选取2015年1月至2017年6月在我院进行糖尿病微血管病变治疗的64例患者作为研究对象,将其随机分成观察组(丹参注射液联合口服胰激肽原酶肠溶片治疗)和对照组32例(丹参注射液治疗),对比两组患者的临床治疗效果。结果:经过治疗后,观察组的治疗有效率为96.88%,对照组的治疗有效率为90.63%,两组在治疗效果方面相比差异具有显著性(P<0.05)。结论:丹参注射液配合口服胰激肽原酶肠溶片治疗糖尿病微血管病变的临床治疗效果确切,具有临床推广价值。
Objective: To investigate the clinical effect of salvia miltiorrhiza injection and oral kallikrein enteric-coated tablets for the treatment of diabetic microangiopathy. Methods: Sixty-four patients with diabetic microangiopathy treated in our hospital from January 2015 to June 2017 were selected as study subjects and randomly divided into observation group (salvia miltiorrhiza injection combined with oral kallikrein enteric-coated tablets) And control group of 32 cases (Salvia injection treatment), compared the clinical efficacy of two groups of patients. Results: After treatment, the effective rate was 96.88% in the observation group and 90.63% in the control group. The difference between the two groups was significant (P <0.05). Conclusion: Salvia miltiorrhiza injection combined with oral kallikrein enteric-coated tablets for the treatment of diabetic microangiopathy clinical treatment of definite effect, with clinical value.